Revvity

Revvity, newly formed and rebranded in 2023 from the legacy life sciences and diagnostics divisions of PerkinElmer, is a highly dynamic, purpose-built health science solutions company headquartered in Waltham, Massachusetts. Unencumbered by legacy industrial businesses, Revvity is strictly focused on accelerating scientific discovery and vastly improving clinical diagnostics. Operating as a massive global enterprise, the company generates nearly $2.9 billion in annual revenue and employs over 11,000 personnel worldwide, heavily driving innovation across pharmaceutical research, academic laboratories, and clinical facilities.

The company boasts an incredibly robust, highly diverse portfolio that seamlessly spans the entire continuum from early-stage, complex benchtop research to precise clinical diagnostic testing. In the life sciences sector, Revvity is globally renowned for its highly advanced in vivo imaging systems, incredibly vast catalog of specialized genomic and proteomic reagents (bolstered by its acquisition of BioLegend), and highly automated liquid handling robotics.

In the diagnostics sphere, Revvity holds an undisputed, absolute global dominance in newborn screening. Their advanced mass spectrometry and assay technologies are critical to global public health, having actively screened over 700 million babies globally over the last 25 years for severe, rare genetic and metabolic disorders, saving countless lives through early detection. They are also massive players in immunodiagnostics and applied genomics.

Furthermore, Revvity heavily emphasizes seamless workflow automation and advanced bioinformatics—driven by its Revvity Signals software—uniquely ensuring that massive streams of raw biological data are rapidly and accurately transformed into highly actionable scientific and clinical insights. With a renewed, highly intense focus on human health, Revvity acts as a deeply critical catalyst for global biotech innovation.